

Assessing the utility of testing aluminium levels in dialysis patients

Hemodialysis International 2015; 19:256–262

Ashish K. Sharma, Nigel D. Toussaint, Janice Pickering, Tony Beeston, Edward R. Smith, Stephen G. Holt

Questions prepared by Alfred John Vincent, RMH

1. What are the manifestations of Aluminium overload in patients with renal failure?
2. Why is Acute or Chronic Al toxicity rare in modern practice?
3. What is the major source of Al exposure in patients with end stage kidney disease (ESKD)?
4. What are the KDOQI guidelines recommended for Al toxicity in patients receiving Al based medications?
5. How many patients were measured for plasma Al over the 4 year period in RMH for this study?
6. Plasma Al levels in dialysis patients declined every year in the study which relates to?
7. What were the limitations of this RMH study?
8. What was the summary of this study?

Thanks to Dr. Nigel Toussaint for giving consent to use this article.